Related Experiment Videos
K A Aitbaev1, I T Murkamilov, V V Fomin
1Research Institute of Molecular Biology and Medicine at the National Center of Cardiology and Therapy Named After acad. M. Mirrakhimov.. fake@neicon.ru.
Insights
This review examines how lipid-lowering therapy impacts cardiovascular risk and kidney function in chronic kidney disease (CKD) patients. It highlights new treatments and nutritional advice for managing dyslipidemia in CKD.
Area of Science:
- Nephrology
- Cardiology
- Pharmacology
Background:
- Chronic kidney disease (CKD) prevalence is rising, posing significant public health challenges.
- CKD is linked to end-stage renal disease (ESRD) requiring costly treatments and increased cardiovascular disease (CVD) risk.
- Hyper- and dyslipidemia significantly influence renal dysfunction progression and CVD development in CKD patients.
Purpose of the Study:
- To review the effects of hypolipidemic therapy on cardiovascular risk reduction in CKD patients.
- To evaluate the impact of lipid-lowering therapy on slowing renal dysfunction in pre-dialysis, dialysis, and kidney transplant patients.
- To present current recommendations on nutrition, novel therapeutic approaches, and future prospects for lipid-lowering drugs in CKD.
Main Methods:
- Systematic review of studies evaluating hypolipidemic therapy in CKD populations.
- Analysis of data on cardiovascular risk and renal function changes.
- Inclusion of nutritional recommendations and emerging therapeutic strategies.
Main Results:
- Hypolipidemic therapy demonstrates potential in reducing cardiovascular risk in CKD patients.
- Evidence suggests lipid-lowering interventions can slow the progression of renal dysfunction.
- The review synthesizes findings across pre-dialysis, dialysis, and post-transplant stages.
Conclusions:
- Lipid management is crucial for mitigating cardiovascular complications in CKD.
- Hypolipidemic therapy offers a viable strategy for slowing CKD progression.
- Future research should focus on novel lipid-lowering agents and personalized nutritional interventions for CKD.
Abstract:
Steady increase in the prevalence of chronic kidney disease (CKD) is a serious public health problem, since CKD potentially leads to the development of end-stage renal disease (ESRD) that requires high-cost replacement therapy and is closely associated with increased risk of developing cardiovascular diseases (CVD), which are the cause of death in most patients. Progression of renal dysfunction and development of CVD are significantly affected by hyper- and dyslipidemia. This review contains results of studies evaluating the effect of hypolipidemic therapy on reduction of cardiovascular risk and slowdown of renal dysfunction in patients with CKD at pre-dialysis and dialysis stages of renal failure, as well as in patients with kidney transplant. In addition, recommendations on nutrition and new therapeutic approaches to lipid-lowering therapy in patients with CKD, as well as prospects for the usage of new hypolipidemic drugs are also presented.